杂志文章@ 1438- 8871% I JMIR出版物V 24% N 卡塔尔世界杯8强波胆分析5% P e37480% T 8周自我管理的基于家庭的虚拟现实程序对慢性腰痛的治疗效果持久性:随机临床试验随访研究% a Garcia,Laura % a Birckhead,Brandon % a Krishnamurthy,Parthasarathy % a Mackey,Ian % a Sackman,Josh % a Salmasi,Vafi % a Louis,Robert % a Castro,Carina % a Maddox,Roselani % a Maddox,Todd % a Darnall,Beth D %+ AppliedVR, 16760 Stagg St, Suite 216, CA Van Nuys, 91406，美国，1 5129478494，tmaddox@appliedvr.io %K行为健康%K慢性腰痛%K治疗%K虚拟现实%D 2022 %7 25.5.2022 %9原始论文%J J医学互联网Res %G英文%X背景:我们之前在一项双盲随机安慰剂对照研究中报道了一项为期8周的家庭治疗沉浸式虚拟现实(VR)计划的疗效。自我报告慢性腰痛的社区成年人被随机1:1接受(1)56天沉浸式治疗性疼痛缓解技能VR计划(EaseVRx)或(2)56天假VR计划。治疗后即刻结果显示治疗性VR在减轻疼痛强度方面优于假VR;与疼痛相关的活动、情绪和压力干扰(但不影响睡眠);生理功能;还有睡眠障碍。治疗后3个月，治疗性VR在减少疼痛强度和疼痛对活动、压力和睡眠的干扰方面保持优势(新发现)。目的:本研究评估治疗后6个月的组间和组内治疗效果，以确定家庭治疗VR的扩展疗效、疗效大小和临床重要性。 Methods: E-surveys were deployed at pretreatment, end-of-treatment, and posttreatment months 1, 2, 3, and 6. Self-reported data for 188 participants were analyzed in a mixed-model framework using a marginal model to allow for correlated responses across the repeated measures. Primary outcomes were pain intensity and pain-related interference with activity, mood, stress, and sleep at 6 months posttreatment. Secondary outcomes were Patient-Reported Outcome Measurement Information System (PROMIS) sleep disturbance and physical function. Results: Therapeutic VR maintained significant and clinically meaningful effects 6 months posttreatment and remained superior to sham VR for reducing pain intensity and pain-related interference with activity, stress, and sleep (ds=0.44-0.54; P<.003). Between-group comparisons for physical function and sleep disturbance showed superiority of EaseVRx over sham VR (ds=0.34; P=.02 and ds=0.46; P<.001, respectively). Participants were encouraged to contact study staff with any problems experienced during treatment; however, no participants contacted study staff to report adverse events of any type, including nausea and motion sickness. Conclusions: Our 8-week home-based VR pain management program caused important reductions in pain intensity and interference up to 6 months after treatment. Additional studies are needed in diverse samples. Trial Registration: ClinicalTrials.gov NCT04415177; https://clinicaltrials.gov/ct2/show/NCT04415177 International Registered Report Identifier (IRRID): RR2-10.2196/25291 %M 35612905 %R 10.2196/37480 %U //www.mybigtv.com/2022/5/e37480 %U https://doi.org/10.2196/37480 %U http://www.ncbi.nlm.nih.gov/pubmed/35612905